Pharmala Biotech Holdings Inc.
CNQ: MDMA.CN0.00 n/a
+0.00%(+0.00)
Key facts
- Exchange
- Canadian Securities Exchange
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Nicholas Kadysh
- Headquarters
- Vancouver, Canada
- IPO year
- 2022
- Market cap
- CA$16.3M
- Website
- https://pharmala.ca
Loading MDMA…
Loading profile data…Frequently asked questions about MDMA
What does Pharmala Biotech Holdings Inc. (MDMA.CN) do?
Pharmala Biotech Holdings Inc., doing business as PharmAla, focuses on the developing, manufacturing, and commercializing of substituted methylenedioxy-phenethylamines (MDXX) active pharmaceutical ingredients. It also provides MDXX class compounds, such as 1,3-Benzodioxolyl-Nmethylbutanamine (MBDB); and 3,4-Methylenedioxy-N-ethylamphetamine (MDE...
Where does MDMA.CN trade?
Pharmala Biotech Holdings Inc. (MDMA.CN) trades on the Canadian Securities Exchange.
What sector is MDMA.CN in?
Pharmala Biotech Holdings Inc. (MDMA.CN) operates in the Healthcare sector, specifically in the Biotechnology industry.
Who is the CEO of Pharmala Biotech Holdings Inc.?
Nicholas Kadysh is the chief executive officer of Pharmala Biotech Holdings Inc. (MDMA.CN).
Where is Pharmala Biotech Holdings Inc. headquartered?
Pharmala Biotech Holdings Inc. is headquartered in Canada.
Does MDMA.CN pay a dividend?
Pharmala Biotech Holdings Inc. (MDMA.CN) does not currently pay a regular dividend. Check the dividends tab for any historical or special distributions.
When did MDMA.CN go public?
Pharmala Biotech Holdings Inc. (MDMA.CN) completed its initial public offering in 2022.